How and when I do allogeneic transplant in CLL
作者： John G. Gribben
DOI: 10.1182/BLOOD-2018-01-785998
关键词:
摘要: Allogenic stem cell transplantation (allo-SCT) has been considered the treatment of choice for high-risk patients with chronic lymphocytic leukemia (CLL) and only approach offered curative intent in this disease. The availability novel agents, including B-cell receptor inhibitors ibrutinib, acalabrutinib, idelalisib, as well venetoclax, which targets BCL2 pathway, success these agents treating disease have made it more difficult to assess who should be allo-SCT when course. In review, I will discuss different options available CLL how fits into algorithm era agents.
ashpublications.org
bloodjournal.org参考文章(64)
Shimon Slavin, Arnon Nagler, Ella Naparstek, Yossi Kapelushnik, Memet Aker, Gabriel Cividalli, Gabor Varadi, Mark Kirschbaum, Aliza Ackerstein, Simcha Samuel, Avraham Amar, Chaim Brautbar, Ofira Ben-Tal, Amiram Eldor, Reuven Or, Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases Blood. ,vol. 91, pp. 756- 763 ,(1998) , 10.1182/BLOOD.V91.3.756.756_756_763
Erick Xavier, Jérôme Cornillon, Annalisa Ruggeri, Patrice Chevallier, Jan J. Cornelissen, Niels S. Andersen, Natacha Maillard, Stephanie Nguyen, Didier Blaise, Eric Deconinck, Hendrik Veelken, Noel Milpied, Michel Van Gelder, Regis Peffault de Latour, Eliane Gluckman, Nicolaus Kröger, Johannes Schetelig, Vanderson Rocha, Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, and the Societé Française de Greffe de Moelle et Therapie Cellulaire. Biology of Blood and Marrow Transplantation. ,vol. 21, pp. 1515- 1523 ,(2015) , 10.1016/J.BBMT.2015.04.026
I F Khouri, M Keating, M Körbling, D Przepiorka, P Anderlini, S O'Brien, S Giralt, C Ippoliti, B von Wolff, J Gajewski, M Donato, D Claxton, N Ueno, B Andersson, A Gee, R Champlin, Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. Journal of Clinical Oncology. ,vol. 16, pp. 2817- 2824 ,(1998) , 10.1200/JCO.1998.16.8.2817
Peter Dreger, Johannes Schetelig, Niels Andersen, Paolo Corradini, Michel van Gelder, John Gribben, Eva Kimby, Mauricette Michallet, Carol Moreno, Stephan Stilgenbauer, Emili Montserrat, Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? Blood. ,vol. 124, pp. 3841- 3849 ,(2014) , 10.1182/BLOOD-2014-07-586826
Ekaterina Chigrinova, Andrea Rinaldi, Ivo Kwee, Davide Rossi, Paola M. V. Rancoita, Jonathan C. Strefford, David Oscier, Kostas Stamatopoulos, Theodora Papadaki, Francoise Berger, Ken H. Young, Fiona Murray, Richard Rosenquist, Timothy C. Greiner, Wing C. Chan, Ester M. Orlandi, Marco Lucioni, Roberto Marasca, Giorgio Inghirami, Marco Ladetto, Francesco Forconi, Sergio Cogliatti, Hana Votavova, Steven H. Swerdlow, Stephan Stilgenbauer, Miguel A. Piris, Andras Matolcsy, Dominic Spagnolo, Eugene Nikitin, Alberto Zamò, Valter Gattei, Govind Bhagat, German Ott, Emanuele Zucca, Gianluca Gaidano, Francesco Bertoni, Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome Blood. ,vol. 122, pp. 2673- 2682 ,(2013) , 10.1182/BLOOD-2013-03-489518
I. Herth, S. Dietrich, A. Benner, U. Hegenbart, M. Rieger, P. Stadtherr, A. Bondong, T.H. Tran, R. Weide, M. Hensel, W. Knauf, J. Franz-Werner, M. Welslau, M. Procaccianti, M. Görner, J. Meissner, T. Luft, S. Schönland, M. Witzens-Harig, T. Zenz, A.D. Ho, P. Dreger, The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison Annals of Oncology. ,vol. 25, pp. 200- 206 ,(2014) , 10.1093/ANNONC/MDT511
Sameer A. Parikh, Neil E. Kay, Tait D. Shanafelt, How we treat Richter syndrome Blood. ,vol. 123, pp. 1647- 1657 ,(2014) , 10.1182/BLOOD-2013-11-516229
Mohamed L. Sorror, Barry E. Storer, David G. Maloney, Brenda M. Sandmaier, Paul J. Martin, Rainer Storb, Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia Blood. ,vol. 111, pp. 446- 452 ,(2008) , 10.1182/BLOOD-2007-07-098483
Kami J. Maddocks, Amy S. Ruppert, Gerard Lozanski, Nyla A. Heerema, Weiqiang Zhao, Lynne Abruzzo, Arletta Lozanski, Melanie Davis, Amber Gordon, Lisa L. Smith, Rose Mantel, Jeffrey A. Jones, Joseph M. Flynn, Samantha M. Jaglowski, Leslie A. Andritsos, Farrukh Awan, Kristie A. Blum, Michael R. Grever, Amy J. Johnson, John C. Byrd, Jennifer A. Woyach, Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia JAMA Oncology. ,vol. 1, pp. 80- 87 ,(2015) , 10.1001/JAMAONCOL.2014.218
Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka, Thorsten Zenz, Marianna Rossi, Konstanze Döhner, Andreas Bühler, Sebastian Böttcher, Matthias Ritgen, Michael Kneba, Dirk Winkler, Eugen Tausch, Patrick Hoth, Jennifer Edelmann, Daniel Mertens, Lars Bullinger, Manuela Bergmann, Sabrina Kless, Silja Mack, Ulrich Jäger, Nancy Patten, Lin Wu, Michael K Wenger, Günter Fingerle-Rowson, Peter Lichter, Mario Cazzola, Clemens M Wendtner, Anna M Fink, Kirsten Fischer, Raymonde Busch, Michael Hallek, Hartmut Döhner, Gene mutations and treatment outcome in chronic lymphocytic leukemia: Results from the CLL8 trial Blood. ,vol. 123, pp. 3247- 3254 ,(2012) , 10.1182/BLOOD-2014-01-546150